SenseUrine’s compact, non-invasive and affordable device uses biofeedback methods to manage and treat all forms of urinary incontinence.Urinary incontinence, or not having control of when one has to “go” is a major healthcare concern in the US. The embarrassing and inconvenient problem affects about 12 million people of all ages, and all socioeconomic backgrounds, in the kindergarten and in the boardroom.
Hoping to alleviate the condition, and that of bedwetting too, is SenseTech Urology from Gan Shmuel, Israel.
The company, based in the Yozmot high-tech incubator, has invented SenseUrine, a compact, non-invasive and affordable device that uses biofeedback methods to manage and treat bedwetting, and all forms of urinary incontinence.
“If a person has some control over their bladder, we can help them,” says Yuli Lozinski, the company’s CEO and device inventor, who holds a PhD in physics. “Our technology tells them when to go to the toilet.”
The SenseUrine device recently passed clinical trials this past October at Israel’s Rambam Medical Center in Haifa. The device is expected to be ready for US consumers by next year, and will cost about $100 per unit, Lozinski tells ISRAEL21c.
The core technology of SenseUrine is a small computer that measures minute changes in a person’s body temperature around the bladder area. These changes are recorded by the computer and can be correlated to the amount of urine one holds in the bladder.
When the bladder is close to being full, an alarm is set off, which lets a person know that it is time to go to the toilet.
An advantage of the SenseUrine device is that it is relatively simple to use and attaches by suction to the belly. It is about one centimeter thick and covers only a five by 10 cm area on the stomach.
Lozinski says that it can be used by bedwetters as young as four years of age, with no upper age limit for treating bedwetting and incontinence.
Not only can SenseUrine aid a person to avoid unpleasant situations and strife, it has a therapeutic benefit also. After some period of use, the device can help train a person’s bladder.
When one is better able to identify internal cues that indicate the time to go to the toilet, the person may be able to time a toilet visit without the aid of the alarm, the company predicts.
Around the same time as SenseUrine’s expected US release, SenseTech also plans to commercialize a second novel device, now in the works. Based on the same heat-sensing mechanisms, this second device can be worn on the hand, and can alert a person with diabetes about their blood glucose levels.
The company’s medical advisor is Dr. Ilan Gruenwald, a senior urologist from the Rambam Medical Center. He is also chief urologist of Israel’s National Center for Continence, and a member of the WHO committee for “promotion and education of incontinence worldwide.”
The company’s web details, promote SenseUrine by stating that it can adequately manage incontinence, so that “bladder control problems need not interfere with a healthy, productive and active lifestyle.”